首页> 外文期刊>Asian Pacific Journal of Cancer Prevention >Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients
【24h】

Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients

机译:ER / PR和HER2所定义的乳腺癌分子亚型:与Ivorian患者的临床病理参数相关联

获取原文
           

摘要

Background: Breast cancer is a heterogeneous disease that represents a major public health problem. The immunohistochemical determination of breast cancer subtypes with regard to estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2) status can contribute to improved selection of therapy and patientcare. The purpose of this study was to determine the prevalence of the molecular breast cancer subtypes and to assess their associations with classical clinicopathologic parameters for better therapeutic decisions in women with breast cancer in the Ivory Coast. Materials and Methods: Formalin-fixed and paraffin-embedded blocks of patients diagnosed with primary breast carcinoma were subjected to immunohistochemical assay for the assessment of ER/RP and HER2 expression. The one-way analysis of variance evaluated the difference between breast cancer subtypes and mean age of patients. The Chi-square Test was used to compare standard clinicopathologic prognostic parameters with tumor subtypes. Results. Among 302 patients, 57% were premenopausal and 43% were postmenopausal. The invasive ductal carcinoma not otherwise specified (IDC NOS) (82.8%) was the most frequent histological type, and the tumor grade 2 (56%) was predominant followed by grade 3 (20.9%). The proportion of positivity of ER, PR, and HER2 was 56%, 49%, and 15.6%, respectively. Half of patients of this study (51.6%) had luminal A breast tumor type followed by TN (32.1%). Other subtypes were luminal B (10.1% ) and non-luminal HER2+ (6.3%). Conclusions. The findings of the present study are in line with the literature and should assist in management of breast cancer in our country.
机译:背景:乳腺癌是一种异质疾病,代表了一个主要的公共卫生问题。关于雌激素受体(ER),孕激素受体(PR)和人表皮生长因子受体(HER2)状态的免疫组织化学测定乳腺癌亚型和人表皮生长因子受体(HER2)状态有助于改善治疗和患者的选择。本研究的目的是确定分子乳腺癌亚型的患病率,并评估其与古典临床病理参数的关联,以便在象牙海岸患有乳腺癌的妇女更好的治疗决策。材料和方法:福尔马林固定和石蜡包埋的患者患者被诊断出患有原发性乳腺癌的患者进行免疫组化测定,用于评估ER / RP和HER2表达。方差单向分析评估了乳腺癌亚型与患者平均年龄的差异。 Chi-Square试验用于将标准临床病理学预后参数与肿瘤亚型进行比较。结果。在302名患者中,57%的前生物术,43%是绝经后缺血。未指定的侵入性导管癌(IDC NOS)(82.8%)是最常见的组织学型,肿瘤级(56%)是主要的,其次为3级(20.9%)。 ER,PR和HER2的正常性分别分别为56%,49%和15.6%。本研究的一半患者(51.6%)含有乳腺肿瘤型,然后是TN(32.1%)。其他亚型是Luminal B(10.1%)和非腔HER2 +(6.3%)。结论。本研究的结果符合文献,并应协助我国乳腺癌的管理。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号